Table 2.
Investigations at baseline
| Control | Spironolactone | |||
|---|---|---|---|---|
| Baseline investigations |
N = 262 |
N = 265 |
||
| Shuttle walk-test | Median | Quartiles 1 & 3 | Median | Quartiles 1 & 3 |
| Number of shuttles completed | 50 | (32 to 70) | 48 | (33 to 65) |
| Breathlessness score after exercise | 5 | (3 to 7) | 5 | (3 to 7) |
| Post-exercise heart rate, b.p.m. | 76 | (64 to 93) | 76 | (64 to 90) |
| Post-exercise, systolic BP, mmHg | 165 | (144 to 187) | 165 | (144 to 188) |
| Electrocardiogram and echocardiography | ||||
| QRS duration (ms) | 92 | (84 to 102) | 92 | (84 to 108) |
| LV end-diastolic volume index (mL/m2) | 42 | (36 to 49) | 41 | (35 to 48) |
| LV ejection fraction (%) | 63 | (57 to 66) | 63 | (59 to 67) |
| Left ventricular mass index (g/m2) | 95 | (81 to 113) | 94 | (81 to 111) |
| Men | 97 | (79 to 103) | 94 | (82 to 111) |
| Women | 88 | (79 to 103) | 96 | (81 to 109) |
| Left atrial volume index (mL/m2) | 31 | (26 to 37) | 30 | (26 to 35) |
| Early mitral flow velocity (E) m/s | 0.7 | (0.6 to 0.8) | 0.7 | (0.6 to 0.8) |
| Late (atrial) mitral flow velocity (A) m/s | 0.8 | (0.7 to 0.9) | 0.8 | (0.7 to 0.9) |
| E/A ratio | 0.8 | (0.7 to 1.0) | 0.8 | (0.7 to 1.0) |
| E/ early diastolic tissue velocity (e’) ratio | 9.4 | (7.5 to 11.8) | 9.2 | (7.6 to 11.3) |
| Tricuspid annular plane systolic excursion | 22.4 | (16.7 to 26.6) | 21.7 | (17.5 to 26.2) |
| Blood tests | ||||
| Haemoglobin, g/dL | 14.1 | (13.2 to 14.9) | 14.0 | (13.1 to 14.9) |
| Sodium, mmol/L | 139 | (138 to 141) | 140 | (138 to 141) |
| Potassium, mmol/L | 4.3 | (4.1 to 4.6) | 4.3 | (4.0 to 4.6) |
| Creatinine, µmol/L | 84 | (74 to 98) | 84 | (71 to 100) |
| Galectin-3, µg/L | 16.1 | (13.2 to 19.7) | 16.0 | (13.8 to 19.7) |
| High-sensitivity troponin-T, ng/L | 12.9 | (9.2 to 18.5) | 12.7 | (8.4 to 17.6) |
| Growth differentiation factor, 15 ng/L | 1,421 | (1,011 to 1,954) | 1,467 | (1,076 to 2,207) |
| Collagen markers and NT-proBNP | ||||
| PIIINP, µg/L | 4.0 | (3.0 to 5.2) | 3.9 | (3.2 to 4.9) |
| PICP, µg/L | 80.9 | (67.2 to 97.6) | 79.1 | (63.2 to 97.0) |
| CITP, µg/L | 3.8 | (2.9 to 5.1) | 3.7 | (2.8 to 4.8) |
| MMP-1, µg/L | 10.2 | (6.7 to 15.3) | 10.2 | (6.7 to 17.1) |
| PICP/CITP, ratio | 20.7 | (15.6 to 28.9) | 21.7 | (16.2 to 28.3) |
| NT-proBNP, ng/L (core lab) | 217 | (134 to 334) | 206 | (135 to 368) |
| Galectin-3 below median | ||||
| PIIINP, µg/L | 3.8 | (3.0 to 5.1) | 3.7 | (3.1 to 4.6) |
| PICP, µg/L | 79.2 | (66.5 to 95.6) | 80.4 | (65.4 to 94.8) |
| CITP, µg/L | 3.4 | (2.7 to 4.2) | 3.2 | (2.7 to 4.3) |
| MMP-1, µg/L | 10.2 | (6.5 to 14.0) | 9.1 | (6.7 to 15.5) |
| PICP/CITP ratio | 22.0 | (17.5 to 30.3) | 23.6 | (17.3 to 29.8) |
| NT-proBNP, ng/L (core lab) | 195 | (119 to 292) | 172 | (132 to 296) |
| Galectin-3 above median | ||||
| PIIINP, µg/L | 4.1 | (3.1 to 5.3) | 4.0 | (3.2 to 4.9) |
| PICP, µg/L | 81.2 | (69.9 to 98.7) | 78.4 | (63.1 to 103.2) |
| CITP, µg/L | 4.1 | (3.1 to 5.6) | 4.1 | (3.0 to 5.3) |
| MMP-1, µg/L | 10.2 | (6.7 to 15.7) | 11.3 | (6.7 to 18.8) |
| PICP/CITP, ratio | 19.6 | (14.7 to 25.5) | 19.6 | (14.7 to 26.6) |
| NT-proBNP, ng/L (core lab) | 239 | (145 to 374) | 263 | (140 to 454) |
BP, blood pressure; CITP, collagen type-1 C-terminal telopeptide; LV, left ventricular; MMP-I, matrix metalloproteinase-1; NT-proBNP, amino-terminal B-type natriuretic peptide; PICP, procollagen type-I C-terminal pro-peptide; PIIINP, procollagen type-III N-terminal pro-peptide.